Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Iwamoto S, et al. Among authors: yabuno t. Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26. Cancer Med. 2018. PMID: 30051609 Free PMC article. Clinical Trial.
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Ooki A, et al. Among authors: yabuno t. Cancer Med. 2020 Mar;9(5):1779-1789. doi: 10.1002/cam4.2826. Epub 2020 Jan 21. Cancer Med. 2020. PMID: 31962002 Free PMC article. Clinical Trial.
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Ooki A, et al. Among authors: yabuno t. Cancer Med. 2020 Dec;9(24):9419-9430. doi: 10.1002/cam4.3564. Epub 2020 Nov 21. Cancer Med. 2020. PMID: 33222406 Free PMC article. Clinical Trial.
Impact of early tumor shrinkage on quality of life in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: results of Phase II QUACK trial.
Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Ooki A, et al. Among authors: yabuno t. BMC Cancer. 2022 Jun 28;22(1):711. doi: 10.1186/s12885-022-09811-x. BMC Cancer. 2022. PMID: 35765021 Free PMC article. Clinical Trial.
Clinicopathological study on pineocytoma.
Tsunoda S, Sakaki T, Tsujimoto M, Yabuno T, Tsuzuki T, Nakamura M, Hiramatsu K, Morimoto T, Boku E, Iwanaga H, et al. Tsunoda S, et al. Among authors: yabuno t. Noshuyo Byori. 1995 Mar;12(1):31-7. Noshuyo Byori. 1995. PMID: 7795727
Immunohistochemical study of glutathione S-transferase-pi in meningiomas.
Nakamura M, Tsunoda S, Sakaki T, Konishi N, Hiasa Y, Tsuzuki T, Yabuno T, Takemura K. Nakamura M, et al. Among authors: yabuno t. Neurol Med Chir (Tokyo). 1995 Nov;35(11):787-90. doi: 10.2176/nmc.35.787. Neurol Med Chir (Tokyo). 1995. PMID: 8657328 Free article.
25 results